NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study

Syed, Mubbasher; Mushtaq, Sajid; Loya, Asif; Hassan, Usman

doi:10.1016/j.anndiagpath.2020.151660

Cited by 15 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histologically, the tumor is characterized by poorly differentiated small round cells with an abrupt transition to hyaline cartilage [ 3 ]. The immunohistochemical stains are usually positive for NKX2.2, CD99, S100, and SOX9 [ 15 ]. Recently, SOX-9 has been reported as a marker that stains both the undifferentiated and the cartilaginous components in ESMC [ 16 , 17 ].…”

Section: Discussionmentioning

confidence: 99%

A Rare Case Report of Mesenchymal Chondrosarcoma with Pancreatic Metastasis

Chen

Chou

2022

Medicina

View full text Add to dashboard Cite

Background: Mesenchymal chondrosarcoma is a rare but aggressive subtype of sarcoma. The majority of involvement locates in the axial skeleton. Treatment modalities include radical surgery, local radiotherapy, and systemic chemotherapy. However, the long-term survival outcome remains poor. Case presentation: We present the case of a 33-year-old male with a palpable chest wall mass for one year, diagnosed with mesenchymal chondrosarcoma with surgical removal. Later, he had an unusual pancreatic tail tumor as the first presentation of disease metastasis which was proven by surgical resection one year later. Conclusion: Although mesenchymal chondrosarcoma locates mainly in the axial skeletal system, extra-skeletal soft tissue or organ involvement might be seen occasionally. Active surveillance with multidisciplinary team management could significantly prolong survival outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

A Rare Case Report of Mesenchymal Chondrosarcoma with Pancreatic Metastasis

Chen

Chou

2022

Medicina

View full text Add to dashboard Cite

show abstract

“…The immunophenotype of mesenchymal chondrosar-Acta Cytologica 2022;66:279-294 DOI: 10.1159/000524260 coma includes S100 protein positivity in the cartilaginous component and CD99 and SOX9 positivity in the small cell population. NKX3.1 is a useful immunohistochemical marker in differentiating mesenchymal chondrosarcoma from its histological mimics [98]. Negative staining for FLI-1 and CD45 help in distinguishing mesenchymal chondrosarcoma from ES and non-Hodgkin lymphoma.…”

Section: Discussionmentioning

confidence: 99%

The Small Round Cell Sarcomas Complexities and Desmoplastic Presentation

Domanski¹

2022

Acta Cytologica

View full text Add to dashboard Cite

Background: Small round cell sarcomas (SRCSs) account for most solid malignancies in the pediatric age group and are a part of group of malignant tumors characterized by heterogenous clinical presentation and overlapping microscopic features of small, round, primitive cells. In addition to the recently established certain genetically defined subset of undifferentiated round cell sarcomas of soft tissue and bone, this group of sarcomas include desmoplastic small round cell tumor, poorly differentiated synovial sarcoma, alveolar rhabdomyosarcoma, mesenchymal chondrosarcoma, and small cell osteosarcoma. Although, those entities share clinical and cytomorphologic features and cannot be unequivocally classified based on clinical presentation and morphology alone. Most of SRCSs characterizes of particular patterns of protein expression or genetic changes and ancillary tests remain necessary to confirm or rule out a specific diagnosis. Subtle but occasionally distinctive cytologic features narrows the number of differential diagnoses and helps to select appropriate ancillary tests necessary for the final diagnosis. Thus, when adequate fine needle aspiration (FNA) biopsy specimen is combined with ancillary tests, a specific histologic diagnosis can be made in almost all cases. However, due to complex cytologic features of SRCS as well as various quality and diversity of FNA smears, there are cases in that cytologic features which do not entirely match the known diagnostic criteria. Summary: The aim of this review was to summarize cytomorphologic criteria and to present rare and divergent cytological features of SRCSs. Careful assessment of clinical presentation, cytological features, immunohistochemical patterns, and molecular alternations is necessary for an accurate diagnosis. Knowing of rare and divergent microscopic findings that does not fit with the known cytological criteria will help to avoid misdiagnosis. Key Messages: The role of FNA biopsies diagnosing soft tissue and bone tumors has been increasing because of the ability of ancillary tests to assist in the diagnosis of specific tumors. SRCSs may be diagnosed accurately in cytology specimens. Access to clinical and radiographic presentation, utility of ancillary tests, understanding complexity of cytological features, and awareness of the rare cytologic findings that differ from that of the established diagnostic criteria are essential to make correct diagnosis.

show abstract

“…Staining in 0 or <5% of cells was graded as negative, staining in 5 to 50% of cells was graded as focal positive and staining in >50% of cells was graded as diffuse positive. 11,12 NKX 3.1 was applied by immunohistochemistry on all these 49 cases. The level of staining of NKX 3.1 was observed by the percentage of nuclear staining seen in tumour cells.…”

Section: Methodsmentioning

confidence: 99%

Expression of NKX 3.1 in Sertoli Cell Tumors

Fatima

Mushtaq

Loya

2022

PAFMJ

View full text Add to dashboard Cite

Objective: To evaluate the NKX3.1 expression by immunohistochemistry in normal testicular parenchyma and in Sertoli cell tumours and Sertoli Leydig cell tumours of the testes and ovary. Study Design: Retrospective longitudinal study. Place and Duration of Study: Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore Pakistan, from 2010-2021. Methodology: We used immunohistochemistry to evaluate the positivity and loss of nuclear expression of NKX3.1 in the Sertoli cell tumour (11 cases), Sertoli Leydig cell tumour (31 cases) and in normal testicular parenchyma (7 cases). Results: In our study, there were 49 cases. All the cases of benign testicular parenchyma expressed positivity with nuclear staining of NKX 3.1 in Sertoli cells. Two out of 11 Sertoli cell tumours expressed positivity with nuclear positivity of NKX 3.1 in Sertoli cell component (18.18%) and 9 of the cases showed loss of staining of NKX 3.1 (81.8%). All Sertoli Leydig cell tumours showed loss of staining of NKX 3.1. Conclusion: Nuclear expression of NKX 3.1 is seen in Sertoli cells of normal testicular parenchyma. This staining is lost in Sertoli cell tumours and Sertoli Leydig cell tumours.

show abstract

NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study

Cited by 15 publications

References 14 publications

A Rare Case Report of Mesenchymal Chondrosarcoma with Pancreatic Metastasis

A Rare Case Report of Mesenchymal Chondrosarcoma with Pancreatic Metastasis

The Small Round Cell Sarcomas Complexities and Desmoplastic Presentation

Expression of NKX 3.1 in Sertoli Cell Tumors

Contact Info

Product

Resources

About